Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Oct 14;115(19):11147-90.
doi: 10.1021/acs.chemrev.5b00116. Epub 2015 Jun 19.

Clinical Translation of Nanomedicine

Yuanzeng Min  1 , Joseph M Caster  1 , Michael J Eblan  1 , Andrew Z Wang  1
Affiliations
Review

Clinical Translation of Nanomedicine

Yuanzeng Min et al. Chem Rev. .

Abstract

PubMed Disclaimer

Figures

Figure 1
Figure 1
Doxorubicin levels in patients' tumor biopsies, comparing free DOX and DOXIL. Reprinted with permission from ref 26. Copyright 2012 Elsevier Ltd.
Figure 2
Figure 2
Kaplan-Meier curves of survival for all randomized patients assigned to treatment with pegylated liposomal doxorubicin or topotecan. Reprinted with permission from ref 45. Copyright 2004 Elsevier Ltd.
Figure 3
Figure 3
Rate of cardiac events versus cumulative anthracycline dose. Patients who had a baseline and at least one additional multigated blood-pool imaging (MUGA) scan during treatment. Cumulative percentage of events versus cumulative anthracycline dose, protocol-defined cardiac events. Reprinted with permission from ref 50. Copyright 2004 Oxford University Press. hazard ratio (HR) = 3.16; 95% confidence interval (CI) 1.58–6.31; P < 0.001; PLD, n = 254; doxorubicin, n = 255.
Figure 4
Figure 4
Lipid amphotericin B formulations. DMPC, dimyristoyl phospitidylcholine; DMPG, dimyristoyl phospitidylcglycerol; HSPC, hydrogenated soy phosphatidylcholine; DSPG, distearoyl phosphitidylcholine. Reprinted with permission from ref 94. Copyright 1996 Oxford University Press.
Figure 5
Figure 5
SPIONs for biomedical application. Reprinted with permission from ref 316. Copyright 2012 American Chemical Society.
See this image and copyright information in PMC

References

    1. Wagner V, Dullaart A, Bock AK, Zweck A. The Emerging Nanomedicine Landscape. Nat Biotechnol. 2006;24:1211–1217. - PubMed
    1. Webster TJ. Nanomedicine: what's in a definition? Int J Nanomed. 2006;1:115–116. - PMC - PubMed
    1. Etheridge ML, Campbell SA, Erdman AG, Haynes CL, Wolf SM, McCullough J. The Big Picture on Nanomedicine: the state of investigational and approved nanomedicine products. Nanomedicine. 2013;9:1–14. - PMC - PubMed
    1. Hay M, Thomas DW, Craighead JL, Economides C, Rosenthal J. Clinical Development Success Rates for Investigational Drugs. Nat Biotechnol. 2014;32:40–51. - PubMed
    1. Lipsky MS, Sharp LK. From Idea to Market: the drug approval process. J Am Board Fam Med. 2001;14:362–367. - PubMed

Publication types